Erik Schwetje

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis

David Jayne, Brad H. Rovin, Eduardo Mysler et al. · Annals of the Rheumatic Diseases · 2022 · 177 citations · Full text

Long‐Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open‐Label Extension Study

Winn Chatham, Richard Furie, Amit Saxena et al. · Arthritis & Rheumatology · 2020 · 71 citations · Full text

Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial

David Jayne, Brad H. Rovin, Eduardo Mysler et al. · Lupus Science & Medicine · 2023 · 40 citations · Full text

Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study

Ian N Bruce, Alireza Nami, Erik Schwetje et al. · The Lancet Rheumatology · 2020 · 24 citations

Autoimmune Disease, Scleroderma, Systemic Lupus Erythematosus Treatment +13

POS0690 RANDOMIZED, CONTROLLED, PHASE 2 TRIAL OF TYPE 1 IFN INHIBITOR ANIFROLUMAB IN PATIENTS WITH ACTIVE PROLIFERATIVE LUPUS NEPHRITIS

David Jayne, B.H. Rovin, Eduardo Mysler et al. · Annals of the Rheumatic Diseases · 2021 · 16 citations · Full text